BioTuesdays

Tag - Louise Chen

Clarus-Therapeutics
Markets

Cantor starts Clarus Therapeutics at OW; PT $20

Cantor Fitzgerald initiated coverage of Clarus Therapeutics (NASDAQ:CRXT) with an “overweight” rating and $20 price target. The stock closed at $8.81 on Sept. 17. Clarus is focused on developing androgen and metabolic...

September 20, 2021
Effector-Therapeutics
Markets

Cantor starts eFFECTOR Therapeutics at OW; PT $50

Cantor Fitzgerald launched coverage of eFFECTOR Therapeutics (NASDAQ:EFTR) with an “overweight” rating and price target of $50. The stock closed at $26.59 on Sept. 10. eFFECTOR is focused on developing a new class of...

September 13, 2021
Jaguar Health Logo
Markets

Cantor starts Jaguar Health at OW; PT $5

Cantor Fitzgerald initiated coverage of Jaguar Health (NASDAQ:JAGX) with an “overweight” rating and price target of $5. The stock closed at $1.49 on July 6. Jaguar Health is a commercial-stage pharmaceuticals company...

July 7, 2021
Cutera
Markets

Cantor starts Cutera at OW; PT $55

Cantor Fitzgerald initiated coverage of Cutera (NASDAQ:CUTR) with an “overweight” rating and 12-month price target of $55. The stock closed at $40.86 on June 1. “Cutera’s comprehensive portfolio of innovative aesthetic...

June 2, 2021
Evolus
Markets

Cantor ups Evolus PT to $20 from $11

Cantor Fitzgerald raised its price target for Evolus (NASDAQ:EOLS) to $20 from $11, following a litigation settlement, which Cantor believes “increases earnings visibility for Evolus, and removes a large overhang on the...

February 22, 2021